[Infliximab].
A number of over-sea study showed the immediate and dramatic anti-inflammatory effects of infliximab(IFX) in patients with rheumatoid arthritis (RA). In addition, significant reduction of bone/joint destruction by IFX was proven in RA patients. On the other hand, some serious adverse effects of IFX were documented. In Japan, IFX was approved as a biological reagent against RA on 2003, and nationwide post marketing surveillance was conducted in the consecutive 5,000 RA patients on IFX. The data showed that 91.6% of patients had overall efficacy as "marked improvement" or "improvement". Serious adverse reaction was reported in 6.2%. Therefore, IFX is very effective and well tolerated in Japanese patients with RA.
Yoshida
Nobuya
N
Department of Medicine II, Hokkaido University Graduate School of Medicine.
Hashimoto
Toko
T
Atsumi
Tatsuya
T
Koike
Takao
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011014:Pneumonia / Q000209:etiology; D011358:Product Surveillance, Postmarketing; D016896:Treatment Outcome; D014376:Tuberculosis / Q000209:etiology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008727:Methotrexate